SCHEMBL2435696

SCHEMBL2435696

Cn1c(=O)c(C(=O)CCC(=O)O)c(O)c2ccc(-c3ccccc3)cc21

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.71
HIF1A Q16665 7/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAOB P27338 1/20 0.46
KDM5B Q9UGL1 2/20 0.46
KDM4A O75164 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
KDM4E B2RXH2 1/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PGR P06401 1/20 0.44
FFAR1 O14842 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437107 0.91 EGLN1 (0.68) EGLN1HIF1ARXRARXRBALDH1A1
SCHEMBL2438080 0.91 EGLN1 (0.61) EGLN1HIF1ARXRARXRBALDH1A1
SCHEMBL2434562 0.85 EGLN1 (0.64) EGLN1HIF1AALDH1A1CYP1A2
SCHEMBL2438583 0.85 EGLN1 (0.61) EGLN1HIF1AALDH1A1NPC1KDM4E
SCHEMBL2441282 0.85 EGLN1 (0.69) EGLN1ALDH1A1KMT2AMEN1RAB9A
SCHEMBL2436224 0.85 EGLN1 (0.63) EGLN1HIF1AALDH1A1
SCHEMBL12291923 0.84 EGLN1 (0.76) EGLN1HIF1AALDH1A1KMT2AMEN1
SCHEMBL2435683 0.83 EGLN1 (1.00) EGLN1HIF1AALDH1A1KMT2AMEN1
SCHEMBL2438424 0.83 EGLN1 (0.74) EGLN1HIF1AALDH1A1KMT2AMEN1
SCHEMBL12291927 0.83 EGLN1 (0.60) EGLN1HIF1AALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP claimed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US claimed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP claimed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US claimed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO claimed
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 EGLN1 6/4885HIF1A 5/4885RXRA 868/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1A 4/4885RXRA 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.